$2.10
-0.50 (-19.23%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PLYX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 2.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)NCT07740512To evaluate the safety and tolerability of PLX-200 in study participants 2 to 15 years old1 with LSDs2 during the treatment period.Non-randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: PLX-200 | Lysosomal Storage Disorders, Sandhoff Disease, Krabbe Disease, CLN2, CLN3 | 24 | 2028-12-31 | in 865 d | 2026-07-31 |
| Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3NCT04637282Efficacy of PLX-200 in CLN3 as assessed by the change in the motor score of the Hamburg Rating Scale compared with that of the Placebo groupRandomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Study has yet to begin and removing to avoid further participant outreach to sponsor | Drug: PLX-200, Placebo | Juvenile Neuronal Ceroid Lipofuscinosis | 0 | 2026-12-31 | in 134 d | 2026-08-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19